926 related articles for article (PubMed ID: 25663685)
1. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Eke I; Cordes N
Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
[TBL] [Abstract][Full Text] [Related]
3. Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Koppenhagen P; Dickreuter E; Cordes N
Radiother Oncol; 2017 Sep; 124(3):370-378. PubMed ID: 28578803
[TBL] [Abstract][Full Text] [Related]
4. Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by β1 integrin inhibition.
Eke I; Dickreuter E; Cordes N
Radiother Oncol; 2012 Aug; 104(2):235-42. PubMed ID: 22748391
[TBL] [Abstract][Full Text] [Related]
5. Towards an integrated understanding of epidermal growth factor receptor biology for radiation therapy: integrins enter.
Willers H; Hong TS
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663686
[No Abstract] [Full Text] [Related]
6. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.
Dickreuter E; Eke I; Krause M; Borgmann K; van Vugt MA; Cordes N
Oncogene; 2016 Mar; 35(11):1353-62. PubMed ID: 26073085
[TBL] [Abstract][Full Text] [Related]
7. EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
Poschau M; Dickreuter E; Singh-Müller J; Zscheppang K; Eke I; Liersch T; Cordes N
Radiother Oncol; 2015 Sep; 116(3):510-6. PubMed ID: 26096850
[TBL] [Abstract][Full Text] [Related]
8. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Hehlgans S; Eke I; Cordes N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e669-76. PubMed ID: 22483702
[TBL] [Abstract][Full Text] [Related]
9. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
10. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
12. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
[TBL] [Abstract][Full Text] [Related]
13. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
14. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Beta1 Integrin and EGFR Targeting in Sphere-Forming Human Head and Neck Cancer Cells.
Zscheppang K; Kurth I; Wachtel N; Dubrovska A; Kunz-Schughart LA; Cordes N
J Cancer; 2016; 7(6):736-45. PubMed ID: 27076856
[TBL] [Abstract][Full Text] [Related]
16. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
[TBL] [Abstract][Full Text] [Related]
17. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
18. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
19. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
